about
Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'IvoireMortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaborationHaematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'Ivoire.High correlation between Framingham equations with BMI and with lipids to estimate cardiovascular risks score at baseline in HIV-infected adults in the Temprano trial, ANRS 12136 in Côte d'Ivoire.Decrease in sexual risk behaviours after early initiation of antiretroviral therapy: a 24-month prospective study in Côte d'Ivoire.Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Côte d'Ivoire, West Africa.A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire.The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire.Medication possession ratio: predicting and decreasing loss to follow-up in antiretroviral treatment programs in Côte d'IvoireLack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire.CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials.AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'IvoireNew indicators for delay in initiation of antiretroviral treatment: estimates for CameroonHigh prevalence of being Overweight and Obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano TrialEstimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Côte d'Ivoire: impact of alternative methods of CD4 count modelling.Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West AfricaAnthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults.Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies.Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West Africa.Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age.Effect of early antiretroviral therapy on sexual behaviors and HIV-1 transmission risk among adults with diverse heterosexual partnership statuses in Côte d'Ivoire.CD4-specific mortality rates among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West Africa.CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters.Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.Identifying patients infected with hepatitis B virus in sub-Saharan Africa: potential for misclassification.WHO guidelines for antiretroviral therapy in serodiscordant couples in sub-Saharan Africa: how many fit?Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis.Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan.Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire.Early antiretroviral therapy initiation in west Africa has no adverse social consequences: a 24-month prospective study.Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.Morbidity after antiretroviral therapy initiation in HIV-1-infected children in West Africa: temporal trends and relation to CD4 count.CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial.Psychosocial correlates of inconsistent condom use among HIV-infected patients enrolled in a structured ART interruptions trial in Côte d'Ivoire: results from the TRIVACAN trial (ANRS 1269).Clinical Outcomes during Treatment Interruptions in Human Immunodeficiency Virus-Hepatitis B Virus Co-infected Patients from Sub-Saharan Africa.Higher mortality despite early ART in HIV and hepatitis B virus coinfected patients with high HBV replication.Depressive symptoms and exposure to efavirenz in West African HIV-infected adults.Decreasing incidence of pregnancy by decreasing CD4 cell count in HIV-infected women in Côte d'Ivoire: a 7-year cohort study.
P50
Q28475790-64B9A3CC-2EA0-47A3-AE06-AA623E115E9DQ30583563-5BE0B5BA-CD8D-4C38-844E-E1443027FC46Q33368355-0F4E2577-7CE6-42E3-B9A8-BA5D1924F27CQ33764308-25C62523-9897-45AC-AFDD-C7088AB7FEB5Q33832234-3BDC384B-B813-44C8-8109-9999E15448D3Q34351266-8D80B2E1-544B-49C8-A58C-505A022B80F6Q34485938-B9C7D039-B035-4B37-92A6-AE117DF811D6Q34630565-01E580C0-39D4-4EC7-A544-97460D96053FQ34777433-61740A5F-7375-437B-9115-0A16A1907812Q35190245-A589554D-0CB3-4733-A133-0FD7B406E6FEQ35560174-2DA1876D-BDEE-4ED8-B7BE-0CBA19BCC864Q35562938-D25D4470-9FF7-456E-8E8A-E5150860C609Q35745688-6183D457-1F04-4A90-8DA0-EF4CA420B82CQ36089497-1794D8F9-7C1F-4E66-A92D-BC0DFADA7DB9Q36621913-8B5EEBF2-72BD-41D3-8F40-3DA956B9B8BCQ36627912-FE17B63A-44C0-4E3C-885A-47B6DA894B2BQ36793768-F88E0B0C-BA82-415C-B148-3D09AC488746Q36793821-AB8FCFAE-89F9-4FE8-906B-9521436C6CF1Q36813326-E1409AB4-8E1C-4DEE-990C-A27BC51A4949Q36915084-F5E2B788-6557-449F-A269-E39356C46842Q37326870-7C77B434-FCBC-481C-B86D-FDA65DAFB520Q37326983-DEC2A9FD-0CD3-460A-B5DF-661955B3934BQ37443074-441CE318-B2B9-437A-B143-03C77D5E29F7Q37578941-B55A64E3-7195-43A2-8151-C4222C492387Q37578944-6A27CDC9-EB14-4EF0-8431-A36F9C058E4FQ38918596-B2414EF9-7703-4890-AE8A-2C13BAFCD814Q38918608-D20FFB09-D482-43F8-901C-7794527264F2Q39146590-694B5579-7341-45FB-9AD0-04631ECA2110Q39448177-3AF4AE6E-F661-4735-B622-97B8529AA9E8Q39448183-69418BBE-BBDD-4326-BAD8-90A8E412D04EQ39821683-0ADC007B-B37B-48BA-8860-F82FD8544402Q39898701-E0C9CB0D-8839-452A-8F86-6EA78BE032EAQ42150097-4A4B5D13-35E1-4AB7-B37C-264D4E060335Q42288974-1B3B29EE-F61B-45DC-BFD2-BF31BF43999FQ44471772-DDC8B676-539F-4A4F-BF57-8F1BBB58A206Q44917739-F1B631AA-B850-4E21-99D0-E37159CF8365Q45324809-3294CFDF-BCD0-4331-9836-6EEABEF1DBF3Q45326464-C28756A7-8FC5-4981-B84D-64B311F8254DQ46127982-BFDEB887-2EE9-4525-B52E-975CE72B02D9Q46161417-2CBF52D2-BBF1-4D66-A6B5-4F9B2D02412D
P50
name
Delphine Gabillard
@en
type
label
Delphine Gabillard
@en
prefLabel
Delphine Gabillard
@en